Acrivon Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.47.

EBIT: As of FY2025 Q3, the actual value is USD -21.19 M.

Segment Revenue

• The company has not generated any revenue from drug sales as of September 30, 2025, and does not expect to generate revenue in the foreseeable future from drug sales.

Operational Metrics

• Net Loss: The net loss for the three months ended September 30, 2025, was $18.2 million, compared to $22.4 million for the same period in 2024.
• Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $13.6 million, a decrease from $18.9 million for the same period in 2024.
• General and Administrative Expenses: General and administrative expenses were $6.0 million for the three months ended September 30, 2025, consistent with the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $48.4 million, compared to $48.3 million for the same period in 2024.
• Net Cash Provided by Investing Activities: Net cash provided by investing activities was $44.6 million for the nine months ended September 30, 2025.
• Net Cash Used in Financing Activities: Net cash used in financing activities was $0.6 million for the nine months ended September 30, 2025.

Unique Metrics

• Accumulated Deficit: As of September 30, 2025, the company had an accumulated deficit of $255.9 million.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue conducting preclinical studies and clinical trials for its clinical stage assets, ACR-368 and ACR-2316, and to discover and develop additional drug candidates and drug-tailored OncoSignature tests.
• Non-Core Business: The company is leveraging its proprietary AP3 precision medicine platform for streamlined drug discovery and to develop its internally-discovered pipeline programs.
• Priority: The company expects its existing cash, cash equivalents, and investments to fund its operating expenses and capital expenditure requirements into the second quarter of 2027.